NDAORALSOLUTION
Approved
Jan 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRIMSOL is an oral solution formulation of trimethoprim hydrochloride, a dihydrofolate reductase inhibitor used to treat bacterial urinary tract infections. It is a small-molecule antibiotic that works by inhibiting bacterial DNA synthesis. The solution formulation enables dosing flexibility for patients who cannot take tablets.
LOE Approaching
Product faces declining revenue pressure with LOE approaching; commercial team likely focused on defending market share against generic entry and optimizing institutional relationships.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PRIMSOL offers experience in mature-product commercialization, institutional relationship management, and formulary defense strategies. The role emphasizes account management and hospital/pharmacy channel expertise over field-based sales growth.
Key Account ManagerInstitutional Account Manager
Worked on PRIMSOL at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.